pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Revolution Medicines, Inc. ($RVMD) · news · pharmadog
← back to Revolution Medicines, Inc.
News mentioning $RVMD
28
stories
14d
RevMed’s Rasonque shatters analyst estimates with $198M quarter
biospace
18d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
23d
Alphabet’s GV is one of biotech’s most influential corporate investors
biospace
24d
STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
stat
Oct 19, 26
Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
biopharma dive
Oct 19, 26
Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
biospace
Oct 15, 26
Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline
fiercebiotech
Oct 14, 26
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
biospace
Oct 13, 26
Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
biospace
Oct 9, 26
New data on RevMed’s Rasonque leave potential opening for other treatments
endpoints
Oct 8, 26
STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines
stat
Oct 8, 26
AI biotech Iambic aims for $135M IPO to push cancer drugs through clinic
fiercebiotech
Sep 22, 26
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
fiercebiotech
Sep 21, 26
Opinion: STAT+: The NIH budget should be $100 billion per year
stat
Sep 8, 26
A breakthrough pancreatic cancer drug won approval. They still struggle to access it
stat
Sep 4, 26
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
biopharma dive
Sep 3, 26
RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer
biospace
Aug 29, 26
Landmark approval for pancreatic cancer; Reactions to Lilly’s Phase 1 secrecy; and more
endpoints
Aug 27, 26
RevMed could become ‘next oncology titan’ with Rasonque nod
biospace
Aug 26, 26
RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug
biospace
Aug 26, 26
STAT+: FDA approves new pancreatic cancer drug expected to usher in new era of treatment
stat
Aug 26, 26
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
fda press
Jul 24, 26
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
Jul 17, 26
BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
fiercebiotech
Jun 8, 26
STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments
stat
Jun 4, 26
STAT+: For pancreatic cancer patients, an exciting drug can feel out of reach
stat
May 31, 26
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
stat
May 6, 26
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
onclive